

S2 Table. Characteristics affecting NAC response

	Non-pCR (n=161)	pCR (n=286)	p-value
Age (yr)			
< 60	148 (91.9)	249 (87.1)	0.159
≥ 60	13 (8.1)	37 (12.9)	
Menopausal status	445		
Pre-menopause	111 (68.9)	147 (51.4)	< 0.001
Post-menopause	50 (31.1)	137 (48.6)	
Histology			
IDC	141 (87.6)	262 (91.6)	0.187
Others	20 (12.4)	24 (8.4)	
Nuclear grade	446		
2	82 (50.9)	107 (37.4)	0.007
3	79 (49.1)	178 (62.6)	
Hormone receptor	446		
ER+/PR+	88 (54.7)	53 (19.0)	< 0.001
ER+/PR-	19 (11.8)	52 (18.2)	
ER-/PR+	0	3 (1.0)	
ER-/PR-	54 (33.5)	177 (61.8)	
Docetaxel RDI			
≤ 0.85	8 (5.0)	25 (8.7)	0.187
> 0.85	153 (95.0)	261 (91.3)	
Carboplatin RDI			
≤ 0.85	107 (66.5)	192 (67.1)	0.917
> 0.85	54 (33.5)	94 (32.9)	

IDC, invasive ductal carcinoma; ER, estrogen receptor; NAC, neoadjuvant chemotherapy; pCR, pathologic complete response; PR, progesterone receptor; RDI, relative dose intensity.